Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LPTX 
Leap Therapeutics Inc (LPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LPTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.15% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.23M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta -0.28 | 52 Weeks Range 0.22 - 4.79 | Updated Date 08/29/2025 |
52 Weeks Range 0.22 - 4.79 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.42 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.23% | Return on Equity (TTM) -183.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5858052 | Price to Sales(TTM) 160.1 |
Enterprise Value -5858052 | Price to Sales(TTM) 160.1 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 0.47 | Shares Outstanding 41439500 | Shares Floating 34665824 |
Shares Outstanding 41439500 | Shares Floating 34665824 | ||
Percent Insiders 16.2 | Percent Institutions 22.06 |
Upturn AI SWOT
Leap Therapeutics Inc
Company Overview
History and Background
Leap Therapeutics, Inc., founded in 2011, is a biopharmaceutical company focused on developing targeted cancer therapies. It leverages its antibody discovery platform to develop novel therapeutics.
Core Business Areas
- DKN01 Development: DKN-01 is Leap's lead clinical program, a humanized IgG1 monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed for various solid tumors.
- FLOT-23 program: Leap's FLOT-23 program is in early-stage development.
Leadership and Structure
Christopher Petty is the CEO of Leap Therapeutics. The company has a board of directors and a management team responsible for overseeing various aspects of the business, including research and development, clinical trials, and corporate strategy.
Top Products and Market Share
Key Offerings
- DKN01: DKN-01 is Leap's lead product candidate. It is a humanized IgG1 monoclonal antibody targeting DKK1. The company is targeting multiple cancer indications, including gastric, gastroesophageal junction, and endometrial cancers. Market share is currently 0% as the drug is not yet approved and in clinical trials. Competitors include other companies developing therapies for these indications, such as Keytruda(MRK), Opdivo(BMY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a focus on developing novel therapies for unmet medical needs. The oncology segment is a major area of focus with significant investment and innovation.
Positioning
Leap Therapeutics is positioned as a clinical-stage biopharmaceutical company focusing on targeted therapies for cancer. Its competitive advantage lies in its DKK1 antibody and its potential in treating multiple solid tumors. However, it's a smaller player compared to established pharmaceutical giants.
Total Addressable Market (TAM)
The global oncology market is estimated to be hundreds of billions of dollars. Leap Therapeutics is targeting specific sub-segments within this market. Successful development and commercialization of DKN-01 could capture a significant portion of the TAM for targeted indications.
Upturn SWOT Analysis
Strengths
- Novel DKK1-targeting antibody (DKN01)
- Focus on specific cancer indications
- Strategic partnerships (e.g. BeiGene)
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on the success of DKN01
- Early-stage development pipeline
Opportunities
- Positive clinical trial results for DKN01
- Expansion into new cancer indications
- Potential for acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
- PFE
Competitive Landscape
Leap Therapeutics faces intense competition from larger, more established pharmaceutical companies. Its advantage lies in its novel DKK1-targeting antibody, but it needs to demonstrate clinical efficacy and secure regulatory approvals to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Leap's growth has primarily been focused on advancing its clinical pipeline, particularly DKN01.
Future Projections: Future projections depend heavily on the success of DKN01 clinical trials and potential regulatory approvals. Analyst estimates vary, but positive results could lead to significant growth.
Recent Initiatives: Recent initiatives include advancing clinical trials for DKN01, securing partnerships (e.g., BeiGene), and exploring new indications for its therapies.
Summary
Leap Therapeutics is a clinical-stage biopharmaceutical company with a promising lead product candidate, DKN01. The company's future hinges on the success of its clinical trials. Financial resources remain a concern, and strategic partnerships are crucial for continued development. The company needs to look out for competition in the oncology market and to ensure DKN-01 is approved and has a large market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Leap Therapeutics Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Leap Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2017-01-25 | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director Mr. Douglas E. Onsi J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.leaptx.com |
Full time employees 52 | Website https://www.leaptx.com | ||
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.